TGFB1 and Hepatic fibrosis: Through studies [116–119], tetramethylpyrazine can increase the MMP/TIMP-1 ratio and accelerate the degradation of ECM with antifibrotic effects, block the pathway of TGF-β1 and Nrf2/β-linked protein, inhibit the activation and migration of HSC, increase the storage of lipid droplets within HSC, or exert antifibrotic effects through cellular autophagy, with anti-inflammatory and antioxidant effects, etc., or inhibit hepatic fibrosis by reducing oxidative stress.